S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Modern Day Options Trading For Beginners! (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Modern Day Options Trading For Beginners! (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The "King Of Quants" sees 10X potential... (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Modern Day Options Trading For Beginners! (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Modern Day Options Trading For Beginners! (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The "King Of Quants" sees 10X potential... (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Modern Day Options Trading For Beginners! (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Modern Day Options Trading For Beginners! (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The "King Of Quants" sees 10X potential... (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Modern Day Options Trading For Beginners! (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Modern Day Options Trading For Beginners! (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The "King Of Quants" sees 10X potential... (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:PACB

Pacific Biosciences of California - PACB Stock Forecast, Price & News

$9.58
+0.45 (+4.93%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.20
$9.64
50-Day Range
$8.30
$12.00
52-Week Range
$3.85
$14.20
Volume
2.32 million shs
Average Volume
4.29 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
20.0% Upside
$11.50 Price Target
Short Interest
Bearish
10.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Pacific Biosciences of California in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$378,968 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.24) to ($1.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

731st out of 999 stocks

Analytical Instruments Industry

21st out of 29 stocks


PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Biden's corruption knows no end
Porter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.pixel
Earnings Outlook For Pacific Biosciences
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
2/16/2023
Today
3/29/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
728
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+20.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-314,250,000.00
Net Margins
-244.93%
Pretax Margin
-244.93%

Debt

Sales & Book Value

Annual Sales
$128.30 million
Book Value
$2.49 per share

Miscellaneous

Free Float
243,620,000
Market Cap
$2.37 billion
Optionable
Optionable
Beta
1.67

Social Links


Key Executives

  • Christian O. HenryChristian O. Henry
    President, Chief Executive Officer & Director
  • Mark David van Oene
    Chief Operating Officer
  • Susan G. KimSusan G. Kim
    Chief Financial Officer
  • Stephen W. Turner
    Chief Technology Officer
  • Jonas Korlach
    Chief Scientific Officer













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PACB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PACB, but not buy additional shares or sell existing shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2023?

5 equities research analysts have issued 12 month target prices for Pacific Biosciences of California's shares. Their PACB share price forecasts range from $8.00 to $14.00. On average, they anticipate the company's stock price to reach $11.50 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2023?

Pacific Biosciences of California's stock was trading at $8.18 on January 1st, 2023. Since then, PACB stock has increased by 17.1% and is now trading at $9.58.
View the best growth stocks for 2023 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings data on Thursday, February, 16th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. The biotechnology company had revenue of $27.35 million for the quarter, compared to the consensus estimate of $27.29 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 47.73% and a negative net margin of 244.93%. The firm's revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.30) earnings per share.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.30 million-$27.30 million, compared to the consensus revenue estimate of $27.88 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.36%), Jackson Square Partners LLC (6.64%), Sumitomo Mitsui Trust Holdings Inc. (6.27%), Nikko Asset Management Americas Inc. (6.27%), T. Rowe Price Investment Management Inc. (2.68%) and Point72 Asset Management L.P. (2.36%). Insiders that own company stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $9.58.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.37 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

The company employs 728 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 3/30/2023 by MarketBeat.com Staff